1. Introduction {#sec1-ijms-17-00945}
===============

Gastric cancer (GC), a malignant epithelial cancer disease \[[@B1-ijms-17-00945]\], is associated with a high global incidence of mortality \[[@B2-ijms-17-00945],[@B3-ijms-17-00945]\]. Although surgical resection, together with chemotherapy and radical therapy, shows significant improvement over surgery alone in early-stage GC patients \[[@B4-ijms-17-00945],[@B5-ijms-17-00945]\], GC patients commonly present with late-stage cancer at initial diagnosis owing to the lack of clinical symptoms that would enable early detection \[[@B2-ijms-17-00945],[@B3-ijms-17-00945],[@B6-ijms-17-00945]\]. The five-year survival rate for late-stage GC patients is only about 20%--30% \[[@B7-ijms-17-00945]\]. Thus, additional studies designed to improve early detection of GC are needed to provide better quality of life and longer survival for GC patients. Early diagnosis is critical for greatly reducing the efficiency of peritoneal spread and local/distal metastasis of GC, necessitating the development of new and more sensitive tumor markers for early GC diagnosis and disease monitoring. Conventional plasma/serum-based tumor biomarkers commonly used clinically for early GC diagnosis, including carcinoembryonic antigen (CEA), the carbohydrate antigens (CA), CA19-9, CA72-4, CA125, CA24-2 and CA50, as well as pepsinogen and α-fetoprotein (AFP), have poor specificity and sensitivity \[[@B8-ijms-17-00945],[@B9-ijms-17-00945]\].

MicroRNAs (miRNAs) are small (\~22 bp) nucleic acids that function by regulating the expression of downstream target genes \[[@B10-ijms-17-00945]\]. Their dysregulation has been reported to be involved in pathogenic processes underlying GC tumorigenesis and progression, including cell growth, invasion, metastasis, and apoptosis. Moreover, miRNAs are stable and persistent among individuals of the same species, even for several years in formalin-fixed, paraffin-embedded tissues and body fluids, such as plasma/serum, urine, saliva, and milk \[[@B11-ijms-17-00945],[@B12-ijms-17-00945],[@B13-ijms-17-00945],[@B14-ijms-17-00945],[@B15-ijms-17-00945]\]. Therefore, aberrantly expressed miRNAs are potentially useful biomarkers for GC screening, diagnosis, prognosis and disease monitoring, as well as therapeutic targets.

A number of researchers have explored the possibility of using miRNAs as biomarkers. Here, we summarize major, up-to-date information on the subject, focusing on discoveries from systematic analysis of miRNA profiling, microarray profiling and quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR) profiling approaches. Specifically, we discuss plasma/serum-based, GC-related circulating miRNAs and their clinical application, focusing particularly on their application as diagnostic and prognostic indicators. We also review tissue-based, GC-related miRNA biomarkers and their downstream targets in GC, as well as plasma/serum-based, GC-associated circulating miRNAs and their clinical applications, focusing especially on early diagnosis. Moreover, we examine correlations among significant clinical parameters and prognostic indicators, and discuss recurrence monitoring and therapeutic options in GC. miRNA biomarkers with potential applications in GC are listed in [Table 1](#ijms-17-00945-t001){ref-type="table"}, [Table 2](#ijms-17-00945-t002){ref-type="table"}, [Table 3](#ijms-17-00945-t003){ref-type="table"} and [Table 4](#ijms-17-00945-t004){ref-type="table"}.

In order to search of all the related literatures, we used PubMed for the GC microRNA expression profiling studies between January 2000 and December 2016. The keyword "miR and gastric cancer" was used. Selected studies should fit the following search criteria: (1) profiling studies in GC patients; (2) including the appropriate adjacent noncancerous gastric tissues or normal plasma/serum for control; (3) including the known cut-off criteria/value of differentially expressed miRNAs; and (4) including the known number of study patients or normal subjects; (5) showing statistical analysis data.

2. Cellular Functions of miRNAs in GC {#sec2-ijms-17-00945}
=====================================

Aberrantly expressed miRNAs serve oncogenic or tumor-suppressor functions in tumorigenesis. They can regulate cell proliferation, cell cycle progression, apoptosis, angiogenesis, cell migration, cell invasion and/or metastasis in GC ([Table 1](#ijms-17-00945-t001){ref-type="table"} and [Table 2](#ijms-17-00945-t002){ref-type="table"}), depending on their target genes. Therefore, a given miRNA may exert dual, opposite functions in GC. Generally, oncogenic miRNAs (oncomiRs) are over-expressed in GC and act to inhibit tumor-suppressor genes. Conversely, tumor-suppressor miRNAs, which inhibit oncogene expression, are usually down-regulated in GC. miRNAs in this category regulate various biological processes to stimulate cancer development.

2.1. GC-Related miRNAs in Cell Proliferation, Cell Cycle, and Apoptosis {#sec2dot1-ijms-17-00945}
-----------------------------------------------------------------------

Accelerated cell proliferation, cell cycle progression or disturbed apoptosis are common features of malignancy that arise through silencing of cell cycle-inhibitory or apoptotic pathway-associated genes. In several malignant tumors, miRNA dysregulation stimulates cell cycle progression by up-regulating cyclin expression or down-regulating the expression of other cell cycle regulators or cyclin-CDK (cyclin-dependent kinase) inhibitors, including members of the p16 family (p15, p16, p18 and p19) and p21 family (p21, p27, p28 and p57) \[[@B212-ijms-17-00945],[@B213-ijms-17-00945],[@B214-ijms-17-00945]\]. Moreover, transforming growth factor (TGF)-β1 has been shown to repress GC cell proliferation through transcriptional up-regulation of p21 \[[@B108-ijms-17-00945]\]. In this context, oncomiR-106b and oncomiR-93 are both up-regulated in GC and target the downstream E2F1 (E2F transcription factor 1) and p21 (cyclin-dependent kinase inhibitor 1A), thereby inhibiting the activity of TGF-β1 \[[@B26-ijms-17-00945]\] and contributing to GC by enhancing cell proliferation.

In addition, these oncomiR clusters are significantly up-regulated in GC. miR-106b-93-25 and miR-222-221 have been reported to inhibit the p21 family CDK inhibitors p57^KIP2^, p21^CIP1^ and p27^KIP1^ \[[@B27-ijms-17-00945]\]. Kim *et al.* showed that over-expression of the miR-222-221 cluster also enhances the growth of GC xenografts in nude mice \[[@B27-ijms-17-00945]\], further reporting that miR-25 targets p57. In addition, both miR-106b and miR-93 down-regulate p21, whereas miR-222 and miR-221 both control p27 and p57. miR-449, which targets cyclin E2 and geminin, among others, and normally promotes senescence and apoptosis, is down-regulated in GC. Consistent with these biological functions, down-regulation of miR-449 in GC promotes G1/S and M/G1 cell cycle progression and cell proliferation \[[@B178-ijms-17-00945]\]. Cui *et al.* \[[@B166-ijms-17-00945]\] reported that the tumor suppressors miR-449 and miR-29a both target p42.3 (suppressor APC domain containing 2) in GC, promoting increased G2/M cell cycle progression and proliferation. In addition to directly targeting CDK inhibitors, miR-24 also modulates anion exhanger-1 (AE1), and thus promotes cell proliferation \[[@B164-ijms-17-00945],[@B165-ijms-17-00945]\]. Moreover, let-7, which targets CDC34, is frequently down-regulated in GC \[[@B105-ijms-17-00945]\].

Some oncomiRs are significantly up-regulated in GC tissues and target downstream tumor-suppressor genes. Zhang *et al.* \[[@B68-ijms-17-00945],[@B69-ijms-17-00945],[@B70-ijms-17-00945],[@B71-ijms-17-00945],[@B72-ijms-17-00945]\] showed that one such oncomiR, miR-21, directly targets the tumor-suppressor gene RECK (reversion-inducing cysteine-rich protein with kazal motifs) and contributes to GC by enhancing cell proliferation and inhibiting apoptosis. Several lines of evidence have revealed that miR-21 also has the ability to stimulate cell invasion and migration. The oncomiR miR-199a was shown to significantly inhibit SMAD4, thereby inhibiting TGF-β1 signaling control over cell proliferation and apoptosis, and promoting anchorage-independent growth in soft agar \[[@B39-ijms-17-00945],[@B58-ijms-17-00945],[@B62-ijms-17-00945],[@B63-ijms-17-00945],[@B64-ijms-17-00945],[@B65-ijms-17-00945]\]. Another oncomiR, miR-23a, was shown to significantly promote GC cell proliferation by silencing its target, the interleukin (IL)-6 receptor (IL6R) \[[@B77-ijms-17-00945],[@B78-ijms-17-00945],[@B79-ijms-17-00945]\].

Conversely, some tumor-suppressor miRs that target downstream oncogenes are significantly down-regulated in GC tissues. Carvalho *et al.* reported that the tumor suppressor miR-101, which targets *EZH2* (enhancer of zeste 2 polycomb repressive complex 2 subunit), *COX-2* (cytochrome c oxidase subunit II), *MCL-1* (myeloid cell leukemia 1) and *FOS* (FBJ osteosarcoma oncogene), has anti-proliferative and anti-metastatic functions in GC \[[@B117-ijms-17-00945],[@B118-ijms-17-00945],[@B119-ijms-17-00945],[@B120-ijms-17-00945]\]. In addition, the tumor suppressor miR-125a, which targets *ERBB2* (erb-b2 receptor tyrosine kinase 2), and miR-129, which targets *CDK6* (cyclin-dependent kinase 6), are also involved in anti-proliferative and pro-apoptotic functions \[[@B24-ijms-17-00945],[@B126-ijms-17-00945],[@B127-ijms-17-00945],[@B131-ijms-17-00945]\]. Similarly, Song *et al.* showed that the tumor suppressor miR-148b, which targets *CCKBR* (cholecystokinin B receptor), is anti-proliferative *in vitro* and anti-tumorigenic *in vivo* \[[@B138-ijms-17-00945]\]. These results suggest that abnormal miRNA expression may increase cell cycle progression through direct or indirect regulation of CDK inhibitors and cell cycle--associated regulators.

In addition, anti-apoptosis is a character of tumorigenesis \[[@B16-ijms-17-00945]\]. miR-106b and miR-93 abrogate TGFβ-induced apoptosis in GC cells by targeting the expression of *BIM*, encoding the pro-apoptotic protein BCL2-like 11, and thereby prevent apoptosis and cause tumor progression \[[@B26-ijms-17-00945]\]. OncomiR-130b in GC cells increases cell viability and anti-apoptosis by targeting TGFβ-induced RUNX3 (runt related transcription factor 3) \[[@B37-ijms-17-00945]\]. Lai *et al.* have also reported that miR-130b suppresses TGFβ-induced BIM expression and apoptosis by targeting RUNX3 in GC cells. Moreover, several oncomiRs, namely miR-15b, miR-16, miR-181b and miR-34, directly target the gene encoding the anti-apoptotic protein Bcl-2, and thus promote apoptosis in GC. The tumor suppressors miR-15b, miR-16 and miR-181b have been shown to inhibit chemotherapeutic drug-induced apoptosis \[[@B47-ijms-17-00945],[@B48-ijms-17-00945]\]. In addition, oncomiR-150 negatively regulates the pro-apoptotic gene *EGR2* (early growth response 2) to accelerate GC growth \[[@B215-ijms-17-00945]\]. Shen *et al.* \[[@B35-ijms-17-00945]\] reported that miR-129-2 targets *SOX4* to induce apoptosis by regulating the relative abundance of pro-apoptotic and anti-apoptotic members of the Bcl-2 family in GC. Bandres *et al.* \[[@B94-ijms-17-00945]\] reported that miR-451 functions as a tumor suppressor by repressing migration inhibitory factor (MIF), thereby activating Bcl-2, EGFR (epidermal growth factor receptor) and the phosphoinositide 3-kinase (PI3K)/Akt pathway in GC \[[@B95-ijms-17-00945],[@B96-ijms-17-00945]\]. Another study showed that ectopic expression of the tumor suppressor miR-375 reduced cell viability in GC cells through the proliferative PI3K/Akt pathway (by targeting JAK2 and PDK1) and the anti-apoptotic NF-κB signaling pathway (by targeting the anti-apoptotic protein 14-3-3ζ) \[[@B86-ijms-17-00945],[@B174-ijms-17-00945],[@B175-ijms-17-00945]\]. Moreover, the tumor suppressor miR-218 regulates COX-2 (cyclooxygenase-2) via the anti-apoptotic NF-κB signaling pathway \[[@B155-ijms-17-00945]\]. These findings suggest that the dysregulated miRs control mitochondria-mediated (intrinsic) and death receptor--mediated (extrinsic) apoptotic pathways through the Bcl-2 family target \[[@B216-ijms-17-00945]\]. Further, dysregulated miRs are also involved in the anti-apoptotic PI3K/Akt and NF-κB signaling pathways which control apoptosis by Bad and the *XIAP* gene \[[@B217-ijms-17-00945]\].

In summary, the abundance of miRs expression may accelerate cell cycle progression through direct or indirect regulation of CDK inhibitors and several cell cycle regulators. Moreover, the abundance of miRs expression also may influence anti-apoptosis or the pro-survival pathway by targeting apoptosis-associated proteins. They may play an important molecular role in GC progression.

2.2. GC-Related miRNAs in Cell Migration, Invasion, and Metastasis {#sec2dot2-ijms-17-00945}
------------------------------------------------------------------

Metastasis, a complex, multistep process that involves cytoskeleton remodeling, matrix metalloproteinases (MMPs), homing receptors and their ligands, intracellular signaling pathways (TGFβ and TGFβ/c-Met) and angiogenesis, is a hallmark of malignant tumors \[[@B218-ijms-17-00945],[@B219-ijms-17-00945]\]. As noted above, Zhang *et al.* \[[@B68-ijms-17-00945]\] identified RECK as a direct target of the oncomiR miR-21, and also found that oncomiR-21 is up-regulated in *Helicobacter pylori-*infected GC tissues. RECK might also possess anti-invasion, anti-metastasis and anti-angiogenesis functions through modulation of MMP2, MMP9 and MMP14 expression. In addition, miR-21 targeting of PDCD4 (programmed cell death 4) is associated with lymph node metastasis and venous invasion. Another report indicated that PTEN (phosphatase and tensin homologue) is a target of miR-21 that promotes anoikis through activation of the PI3K/Akt pathway \[[@B68-ijms-17-00945],[@B72-ijms-17-00945]\]. In addition, Tsai *et al.* \[[@B59-ijms-17-00945]\] have shown that oncomiR-196a/b expression promotes GC cell migration, invasion, and metastasis by increasing radixin (RDX) expression in GC tissues. OncomiR-370 was shown to decrease TGFβ-RII expression and stimulate TGFβ1-induced phosphorylation of Smad3. Thus, oncomiR-370 is capable of triggering cell migration by disturbing the TGFβ signaling pathway \[[@B85-ijms-17-00945]\]. Moreover, oncomiR-215 was shown to target ALCAM (activated leukocyte cell adhesion molecule) and increase GC metastasis \[[@B71-ijms-17-00945]\]. Conversely, the tumor suppressor miR-218 promotes invasion and metastasis by targeting Robo1, and thereby activating the Slit/Robo1 signaling pathway \[[@B156-ijms-17-00945],[@B157-ijms-17-00945],[@B158-ijms-17-00945],[@B159-ijms-17-00945],[@B160-ijms-17-00945]\]. Other tumor suppressors of the let-7 family increase the expression of HMGA2 (high mobility group AT-hook 2), which is associated with tumor invasion and is an independent prognostic factor in GC \[[@B107-ijms-17-00945]\]. Furthermore, members of the miR-200 family increase the epithelial-mesenchymal transition (EMT), and contribute to cell migration by reducing the expression of E-cadherin repressors ZEB1 and ZEB2 (zinc finger E-box binding homeobox 2) \[[@B145-ijms-17-00945],[@B146-ijms-17-00945]\]. Down-regulation of miR-335 was found to be significantly associated with lymph node metastasis, invasion of lymphatic vessels, cell invasion and metastasis through targeting of BCL-w and SP1 (specificity protein 1) \[[@B82-ijms-17-00945],[@B83-ijms-17-00945]\].

Interestingly, the function of miRNAs depends on the expression of their target genes. Previous studies revealed that some miRs could target both oncogenes and tumor-suppressor genes, leading to opposite roles in GC. Accordingly, miR-9 may play dual but opposing roles in GC. Thus, acting as an oncomiR, miR-9 targets CDX2 \[[@B102-ijms-17-00945]\] and increases cell proliferation by facilitating cell cycle progression; conversely, acting as a tumor suppressor, miR-9 targets NF-κB1, cyclin D1, and ETS1 to contribute to anti-proliferation and anti-metastasis \[[@B102-ijms-17-00945],[@B112-ijms-17-00945],[@B113-ijms-17-00945],[@B114-ijms-17-00945]\]. Nakayama *et al.* \[[@B20-ijms-17-00945]\] reported that oncomiR-10b targets HOXD10 (homeobox D10) to promote GC metastasis. However, Kim *et al.* \[[@B116-ijms-17-00945]\] found that miR-10b also represses the expression of MAPRE1 (microtubule associated protein RP/EB family member 1), resulting in the inhibition of colony formation and cell proliferation. Moreover, oncomiR-223 was shown to promote GC invasion and metastasis by targeting EPB41L3 (erythrocyte membrane protein band 4.1-like 3) expression \[[@B76-ijms-17-00945]\]. However, Kang *et al.* \[[@B162-ijms-17-00945],[@B163-ijms-17-00945]\] reported that miR-223 acted as a tumor suppressor, directly targeting STMN1 (stathmin 1) expression to inhibit cell growth and metastasis. Thus, some miRNAs play dual roles through targeting of different genes during GC progression. Further studies will be required to elucidate the details of these different roles.

3. Clinical Applications of MicroRNAs in GC {#sec3-ijms-17-00945}
===========================================

3.1. GC-Related miRNAs as Diagnostic Biomarkers {#sec3dot1-ijms-17-00945}
-----------------------------------------------

Early diagnosis permits effective and radical treatment of GC before it develops to an advanced and metastatic stage. Gastroscopy with biopsy, the current standard clinical practice, is not a good screen for GC on a population basis, and existing biomarkers exhibit poor sensitivity and specificity. Thus, there are currently no reliable diagnostic biomarkers for GC. Multiple or combined biomarker assays are expected to provide more accurate results \[[@B220-ijms-17-00945]\]. Investigators continue their efforts to identify convenient, high-sensitivity, high-specificity, and noninvasive biomarkers for early GC diagnosis \[[@B185-ijms-17-00945]\]. MiRNAs can be released from tumor tissues into bodily fluids, including serum, plasma, urine, tears, amniotic fluid and gastric juice, through the secretion of exosome particles \[[@B15-ijms-17-00945],[@B221-ijms-17-00945],[@B222-ijms-17-00945]\]. Mitchell *et al.* \[[@B15-ijms-17-00945],[@B221-ijms-17-00945],[@B222-ijms-17-00945]\] demonstrated that circulating miRNAs in plasma/serum from GC patients are consistent with those in tissues; therefore, they could be useful as noninvasive biomarkers for the initial diagnosis of GC and assessment of GC recurrence. The most widely investigated biomarkers have been discovered using newer methods, such as systematic analysis of miRNA profiling, miRNA profiling, microarray profiling, and Q-RT-PCR profiling approaches \[[@B223-ijms-17-00945],[@B224-ijms-17-00945],[@B225-ijms-17-00945],[@B226-ijms-17-00945],[@B227-ijms-17-00945]\]. The major plasma/serum-based, GC-related circulating miRNAs that have been suggested as useful GC biomarkers are listed in [Table 3](#ijms-17-00945-t003){ref-type="table"} and [Table 4](#ijms-17-00945-t004){ref-type="table"}.

Liu *et al.* \[[@B111-ijms-17-00945]\] used systematic analysis of miRNA profiling, miRNA profiling to identify a signature of five circulating oncomiRs---miR-1, miR-20a, miR-27a, miR-34 and miR-423-5p---and correlated it with tumor stage. Using receiver-operating characteristic (ROC) curve analyses, these authors evaluated the diagnostic value of this miR signature, showing that it achieved a sensitivity of 80% and a specificity of 81%. They observed that the circulating five-oncomiR signature I exhibited a high diagnostic value, with an area under the ROC curve (AUC) of 0.879. By comparison, the five-oncomiR signature II exhibited an AUC of 0.831, which is higher than that of CEA, with an AUC of 0.503, and CA19-9, with an AUC of 0.6. In a large-scale analysis, four circulating oncomiRs (miR-17-5p, miR-21, miR-106a and miR-106b) significantly distinguished GC patients from healthy controls and pre-operative from post-operative GC patients \[[@B185-ijms-17-00945]\]. Moreover, Valladares-Ayerbes *et al.* \[[@B42-ijms-17-00945]\], using a Cox multivariate regression model, identified circulating oncomiR-200c as a biomarker for GC diagnosis and as an independent prognostic factor for progression-free survival and overall survival in GC patients. Liu *et al.* \[[@B49-ijms-17-00945]\] found that oncomiR-378 in the GC patients was significantly higher than that in the healthy controls. OncomiR-378 exhibited a high diagnostic value, with an AUC of 0.861, a sensitivity of 87.5% and a specificity of 70.7%.

In addition, several oncomiRs circulating in the blood of GC patients can be used as diagnostic biomarkers to distinguish GC patients from healthy individuals. These include miR-1, miR-106a, miR-106b, miR-17, miR-17-5p, miR-18a, miR-192, miR-199a-3p, miR-20a, miR-200c, miR-21, miR-210, miR-218, miR-221, miR-222, miR-25, miR-27a, miR-34, miR-376c, miR-378, miR-421, miR-423-5P, miR-451, miR-486, miR-744, and miR-93 \[[@B26-ijms-17-00945],[@B27-ijms-17-00945],[@B54-ijms-17-00945],[@B68-ijms-17-00945],[@B71-ijms-17-00945],[@B80-ijms-17-00945],[@B111-ijms-17-00945],[@B184-ijms-17-00945],[@B185-ijms-17-00945],[@B186-ijms-17-00945],[@B187-ijms-17-00945],[@B188-ijms-17-00945],[@B190-ijms-17-00945],[@B191-ijms-17-00945],[@B195-ijms-17-00945],[@B196-ijms-17-00945],[@B197-ijms-17-00945],[@B199-ijms-17-00945],[@B200-ijms-17-00945],[@B203-ijms-17-00945],[@B206-ijms-17-00945],[@B207-ijms-17-00945],[@B208-ijms-17-00945]\]. Of these, miR-17-5p, miR-18a, miR-20a, miR-200c, miR-21, miR-218, miR-221, miR-222, miR-25, miR-27a, miR-376c, and miR-744 were found to be significantly elevated in GC patients, and their expression was significantly reduced after surgery \[[@B26-ijms-17-00945],[@B27-ijms-17-00945],[@B54-ijms-17-00945],[@B68-ijms-17-00945],[@B71-ijms-17-00945],[@B80-ijms-17-00945],[@B81-ijms-17-00945],[@B155-ijms-17-00945],[@B187-ijms-17-00945],[@B192-ijms-17-00945],[@B193-ijms-17-00945],[@B195-ijms-17-00945],[@B196-ijms-17-00945],[@B198-ijms-17-00945],[@B199-ijms-17-00945],[@B200-ijms-17-00945],[@B201-ijms-17-00945],[@B202-ijms-17-00945],[@B203-ijms-17-00945],[@B204-ijms-17-00945],[@B205-ijms-17-00945]\].

Conversely, several tumor-suppressor miRNAs circulating in the blood of GC patients can also be used as diagnostic biomarkers to distinguish GC patients from healthy individuals, including miR-122, miR-195-5p, miR-203, miR-218, and miR-375 \[[@B155-ijms-17-00945],[@B189-ijms-17-00945],[@B198-ijms-17-00945],[@B209-ijms-17-00945],[@B210-ijms-17-00945],[@B211-ijms-17-00945]\]. Of these, miR-122, miR-203, and miR-218 were found to be significantly reduced in GC patients, and their expression was significantly increased following surgery \[[@B155-ijms-17-00945],[@B189-ijms-17-00945],[@B198-ijms-17-00945],[@B211-ijms-17-00945]\].

Taken together, these findings suggest that circulating miRNAs are useful, noninvasive biomarkers for early diagnosis or monitoring of cancer survivors after treatment of GC. The significance of these biomarkers compares favorably to the use of the traditional biomarkers CEA or CA19.9 alone.

3.2. GC-Related miRNAs as Prognostic Biomarkers {#sec3dot2-ijms-17-00945}
-----------------------------------------------

To predict GC patient survival time, cancer progression (disease stage), prognostic outcome, lymph node metastasis or response to treatment is challenging. Recurrence is also a key problem leading to the failure of treatments, including radical or chemical treatment and surgical resection. Although the clinical outcome of GC has improved, prognostic indicators capable of predicting recurrence in GC patients after treatment are still lacking. Recently, due to the stability and specificity of expression in tissues and circulation, accumulating evidence has shown that miRNAs can be regarded as novel biomarkers with a potential clinical significance tool for GC patients' outcomes.

In general, the occurrence of a distant metastasis frequently leads to advanced-stage cancer and shorter survival. In this context, it has been shown that oncomiR-10b, miR-21, and miR-212 in GC patients are associated with a high metastasis risk and poor clinical outcomes, including tumor-node-metastasis, tumor size, stage, lymph node metastasis, and five-year survival rate \[[@B69-ijms-17-00945],[@B126-ijms-17-00945],[@B228-ijms-17-00945]\].

Li *et al.* \[[@B229-ijms-17-00945]\] showed that a seven-miRNA signature (miR-10b, miR-21, miR-223, let-7a, miR-338, miR-30a-5p and miR-126) could predict relapse-free and overall survival of GC patients. In addition, oncomiR-20b, miR-150 \[[@B23-ijms-17-00945]\], miR-214 \[[@B24-ijms-17-00945],[@B74-ijms-17-00945]\], miR-375 \[[@B39-ijms-17-00945],[@B74-ijms-17-00945],[@B86-ijms-17-00945],[@B87-ijms-17-00945],[@B88-ijms-17-00945]\], tumor suppressor Let-7g \[[@B24-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945]\], miR-125-5p \[[@B126-ijms-17-00945]\], miR-146a \[[@B24-ijms-17-00945],[@B134-ijms-17-00945]\], miR-218 \[[@B154-ijms-17-00945]\], miR-433 \[[@B24-ijms-17-00945],[@B86-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945],[@B174-ijms-17-00945]\], and miR-451 \[[@B24-ijms-17-00945],[@B94-ijms-17-00945],[@B230-ijms-17-00945]\] are associated with a poor survival prediction in GC. In GC, high expression of miR-195 \[[@B58-ijms-17-00945]\], miR-199a \[[@B39-ijms-17-00945],[@B58-ijms-17-00945],[@B62-ijms-17-00945],[@B63-ijms-17-00945],[@B64-ijms-17-00945],[@B65-ijms-17-00945]\], miR-1952 \[[@B58-ijms-17-00945]\], miR-335 \[[@B82-ijms-17-00945],[@B83-ijms-17-00945]\], miR-375 \[[@B39-ijms-17-00945],[@B74-ijms-17-00945],[@B86-ijms-17-00945],[@B87-ijms-17-00945],[@B88-ijms-17-00945]\], miR-451 \[[@B58-ijms-17-00945],[@B94-ijms-17-00945],[@B95-ijms-17-00945],[@B96-ijms-17-00945]\] and miR-4512 \[[@B39-ijms-17-00945]\], and low expression of miR-142-5p \[[@B39-ijms-17-00945]\] are more likely to indicate relapse or recurrence of GC patients. Moreover, GC patients with over-expression of miR-107 \[[@B28-ijms-17-00945],[@B29-ijms-17-00945],[@B30-ijms-17-00945]\], miR-143 \[[@B40-ijms-17-00945]\], miR-145 \[[@B41-ijms-17-00945],[@B42-ijms-17-00945]\], miR-181b/c \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B55-ijms-17-00945],[@B56-ijms-17-00945]\], miR-196a/b \[[@B59-ijms-17-00945]\], miR-20b \[[@B23-ijms-17-00945],[@B66-ijms-17-00945]\], miR-23a/b \[[@B77-ijms-17-00945],[@B78-ijms-17-00945],[@B79-ijms-17-00945]\], miR-34 \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B55-ijms-17-00945],[@B56-ijms-17-00945]\] and miR-630 \[[@B100-ijms-17-00945]\] and decreased expression of miR-1 \[[@B111-ijms-17-00945]\], miR-1207-5p \[[@B121-ijms-17-00945]\], miR-125a-3p/-5p \[[@B24-ijms-17-00945],[@B125-ijms-17-00945],[@B126-ijms-17-00945],[@B127-ijms-17-00945]\], miR-185 \[[@B140-ijms-17-00945]\], miR-193b \[[@B60-ijms-17-00945]\], miR-20a \[[@B111-ijms-17-00945]\], miR-206 \[[@B150-ijms-17-00945],[@B151-ijms-17-00945]\], miR-215 \[[@B142-ijms-17-00945]\], miR-217 \[[@B153-ijms-17-00945]\], miR-27a \[[@B111-ijms-17-00945]\], miR-29c \[[@B169-ijms-17-00945]\], miR-34a \[[@B172-ijms-17-00945],[@B173-ijms-17-00945]\], miR-423-5p \[[@B111-ijms-17-00945]\], and miR-520d-3p \[[@B99-ijms-17-00945]\] indicate advanced tumor stage or TNM stage. High levels of miR-107 \[[@B28-ijms-17-00945],[@B29-ijms-17-00945],[@B30-ijms-17-00945]\], miR-181b/c \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B55-ijms-17-00945],[@B56-ijms-17-00945]\], miR-192 \[[@B57-ijms-17-00945]\], miR-196a/b \[[@B59-ijms-17-00945]\], miR-20b \[[@B23-ijms-17-00945],[@B66-ijms-17-00945]\], miR-21 \[[@B68-ijms-17-00945],[@B69-ijms-17-00945],[@B70-ijms-17-00945],[@B71-ijms-17-00945],[@B72-ijms-17-00945]\], miR-214 \[[@B24-ijms-17-00945],[@B74-ijms-17-00945]\], miR-23a/b \[[@B77-ijms-17-00945],[@B78-ijms-17-00945],[@B79-ijms-17-00945]\], miR-25 \[[@B26-ijms-17-00945],[@B27-ijms-17-00945],[@B80-ijms-17-00945]\], miR-27a \[[@B23-ijms-17-00945],[@B81-ijms-17-00945]\], miR-630 \[[@B100-ijms-17-00945]\], and miR-650 \[[@B101-ijms-17-00945]\] and decreased levels of Let-7g \[[@B24-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945]\], miR-1207-5p \[[@B121-ijms-17-00945]\], miR-125a-3p/-5p \[[@B24-ijms-17-00945],[@B125-ijms-17-00945],[@B126-ijms-17-00945],[@B127-ijms-17-00945]\] and miR-126 \[[@B128-ijms-17-00945],[@B129-ijms-17-00945],[@B130-ijms-17-00945]\], miR-146a \[[@B24-ijms-17-00945],[@B134-ijms-17-00945]\], miR-148a \[[@B46-ijms-17-00945],[@B135-ijms-17-00945],[@B136-ijms-17-00945],[@B137-ijms-17-00945]\], miR-153 \[[@B139-ijms-17-00945]\], miR-218 \[[@B154-ijms-17-00945],[@B155-ijms-17-00945],[@B156-ijms-17-00945],[@B157-ijms-17-00945],[@B158-ijms-17-00945],[@B159-ijms-17-00945],[@B160-ijms-17-00945]\], miR-22 \[[@B151-ijms-17-00945],[@B161-ijms-17-00945]\], miR-27a \[[@B111-ijms-17-00945]\], miR-29c \[[@B169-ijms-17-00945]\], miR-335 \[[@B171-ijms-17-00945]\], miR-34a \[[@B172-ijms-17-00945],[@B173-ijms-17-00945]\], miR-429 \[[@B177-ijms-17-00945]\], miR-433 \[[@B24-ijms-17-00945],[@B86-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945],[@B174-ijms-17-00945]\] and miR-520d-3p \[[@B99-ijms-17-00945]\] are associated with invasion or LNM, as well as metastasis.

Conversely, the tumor suppressors miR-125a and miR146a are significantly correlated with lymph node metastasis, indicating that they could be prognostic factors of overall survival \[[@B126-ijms-17-00945],[@B134-ijms-17-00945]\]. Other study showed that low expression of let-7 is related to tumor invasiveness and prognosis by targeting HMGA2 \[[@B231-ijms-17-00945]\].

Therefore, many potential predictors have been regarded as beneficial for mediating the prognosis of GC patients and are the basis for targeted therapy. In future, these prognostic miRNAs could be useful for making choices concerning treatment.

3.3. GC-Related miRNAs as Treatment Biomarkers {#sec3dot3-ijms-17-00945}
----------------------------------------------

One miRNA may regulate multi-target gene expression and multiple pathways, affecting the process of tumor development \[[@B232-ijms-17-00945],[@B233-ijms-17-00945],[@B234-ijms-17-00945]\]. Thus, miRNAs are more effective than coding genes as biological regulation molecules.

The methods of current miRNA-mediated treatment are focused on miRNA knockout or silencing the endogenous oncomiRs, including anti-miRNA oligonucleotides (AMOs) \[[@B13-ijms-17-00945]\], miRNA sponges \[[@B235-ijms-17-00945]\], miR-Mask \[[@B236-ijms-17-00945]\], antagomiRs and miRNA inhibitors \[[@B12-ijms-17-00945],[@B237-ijms-17-00945]\]. For example, Chun *et al.* \[[@B200-ijms-17-00945]\] transfected AS-miR-221/222 with liposomes into GC cell line SGC7901 to inhibit GC cell growth and invasion. Moreover, high expression of miR-196a/-196b promotes GC cell migration and invasion. Elevated miR-196a/-196b expression results in decreasing target RDX protein in GC cells and *vice versa*. Similar results were obtained in a mouse model of human GC. Tsai *et al.* \[[@B59-ijms-17-00945]\], through AMOs, used anti-miR-196a/-196b oligonucleotides or the over-expression of RDX, which may serve a therapeutic purpose to inhibit GC metastasis.

Conversely, forced expression the tumor suppressor miRNAs is used to gain the resolution of tumor treatment. miRNA over-expression is often performed by using an *in vivo* or *in vitro* RNA delivery system as in cancer therapeutics, including adeno-associated viruses \[[@B238-ijms-17-00945]\] or nonpathogenic bacteria \[[@B239-ijms-17-00945]\] as a carrier to introduce a specific miRNA or miRNA mimics to up-regulate miRNA \[[@B240-ijms-17-00945]\]. miR-1207-5p and miR-1266 are significantly down-regulated in GC tissues. Over-expression of these two miRs inhibited GC growth through targeting hTERT system *in vitro* and *in vivo*. Chen *et al.* \[[@B241-ijms-17-00945]\] showed a novel therapeutic method for the delivery of these two miRs for GC treatment.

However, some problems must be considered. For example, one miRNA modulates multi-target genes and multiple pathways. Also, the off-target effects are unexpected. Thus, better specificity and an effective miRNA delivery system for a therapeutic strategy must be developed \[[@B242-ijms-17-00945],[@B243-ijms-17-00945]\].

4. Conclusions {#sec4-ijms-17-00945}
==============

miRNA biomarkers have been found at elevated levels in the blood or tissues of patients with tumors. Changes in different biomarkers during tumor progression can help clinicians monitor cancer status. Although higher levels of a biomarker can potentially predict a tumor, other factors may also account for such elevated levels. Dysregulation of tumor markers can occur in response to the presence of a tumor or a change in status, enabling them to be used for a range of applications, including screening, diagnosis, staging, prognosis, and monitoring of recurrence after treatment. The values of these miRNAs as biomarkers will require further confirmation in human GC patients. In the future, an miRNA or an miRNA signature could be a better diagnostic or therapeutic tool than a single gene. However, the challenge is to develop a standard protocol for collecting large specimens, re-analyzing them in a large independent cohort, and validating their significance in clinical applications.

Moreover, several studies have suggested that tumor-derived circulating miRs might be secreted into circulation. Circulating miRs in the plasma/serum of GC patients can be used as diagnostic biomarkers to compare GC patients with healthy controls \[[@B185-ijms-17-00945],[@B244-ijms-17-00945]\]. Most of these biomarkers are more sensitive and specific than the traditional biomarkers CEA or CA19.9 alone \[[@B111-ijms-17-00945],[@B185-ijms-17-00945],[@B190-ijms-17-00945]\]. These findings provide novel indicators for monitoring GC dynamics and early diagnosis for GC to improve survival.

Currently, biomarkers are only used as a reference and not to diagnose the disease *per se*. A professional physician will still need to provide a comprehensive judgment, including choice of tumor marker, evaluation of clinical symptoms, assessment of related imaging performance, and other non-specific factors. Ultimately, the personalized management, diagnosis, and prognosis of the disease can be achieved using a panel of miRNAs.
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AE1: Anion exhanger-1; AFP: Alphafetoprotein; ALCAM: Activated leukocyte cell adhesion molecule; AMOs: Anti-miRNA oligonucleotides; AUCs: Areas under the ROC curves; CA19-9: Carbohydrate antigen 19-9; CCKBR: Cholecystokinin B receptor; CEA: Carcinoembryonic antigen; COX-2: Cyclooxygenase-2; Cyclin-CDK: Cyclin-dependent kinase; CDK6: Cyclin-dependent kinase 6; E2F1: E2F transcription factor 1; EGFR: Epidermal growth factor receptor; EGR2: Early growth response 2; EMT: Epithelial--mesenchymal transition; EPB41L3: Erythrocyte membrane protein band 4.1-like 3; ERBB2: Erb-b2 receptor tyrosine kinase 2; EZH2: Enhancer of zeste 2 polycomb repressive complex 2 subunit; FFPE: Formalin-fixed paraffin-embedded; FOS: FBJ osteosarcoma oncogene; GC: Gastric cancer; HMGA2: High mobility group AT-hook 2; HOXD10: Homeobox D10; IL6R: interleukin (IL)-6 receptor; MAPRE1: Microtubule associated protein RP/EB family member 1; MCL-1: Myeloid cell leukemia 1; MIF: Migration inhibitory factor; miRNAs: MicroRNAs; MMP: Matrix metalloproteinase; NF-κB: Nuclear factor-κB; OncomiRs: Oncogenic miRNAs; OS: Overall survival; p21: cyclin-dependent kinase inhibitor 1A; PDCD4: Programmed cell death 4; PFS: progression free survival; PI3K: phosphoinositide 3-kinase; Post-op: Post-operative; Pre-op: Pre-operative; PTEN: Phosphatase and tensin homologue; Q-RT-PCR: quantitative reverse transcription-polymerase chain reaction; RDX: Radixin; RECK: reversion-inducing cysteine-rich protein with kazal motifs; ROC: Receiver operating characteristic; RUNX3: Runt related transcription factor 3; SP1: Specificity protein 1; STMN1: Stathmin 1; TGF-β1: Transforming growth factor-β1; TNM: Tumor-node-metastasis; Tumor suppressor-miRs: Tumor suppressive miRNAs; ZEB2: Zinc finger E-box binding homeobox 2.
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###### 

Up-regulated miRNAs in tissues for GC.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tissue OncomiRs              Samples                                                   Cell Functions           Target (Official Gene Name)   Clinical Application     References
  ---------------------------- --------------------------------------------------------- ------------------------ ----------------------------- ------------------------ -----------------------------------------------------------------------------------------------------------------------------------
  **let-7b**                   Systematic integrative bioinformatics framework           ND                       ND                            Diagnosis                \[[@B16-ijms-17-00945]\]

  **let-7g**                   GCCLs                                                     Chemosensitivity         ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-10b**                  GCCLs                                                     Metastasis               *HOXD10*                      ND                       \[[@B18-ijms-17-00945],[@B19-ijms-17-00945],[@B20-ijms-17-00945]\]

  **miR-105**                  GCTs                                                      ND                       ND                            Diagnosis                \[[@B21-ijms-17-00945]\]

  **miR-106a**                 GCCLs                                                     Cell cycle               *RB1*\                        ND                       \[[@B22-ijms-17-00945]\]
                                                                                                                  *TIMP2*\                                               
                                                                                                                  *FAS*                                                  

  **miR-106b-93-25 cluster**   GCTs\                                                     Apoptosis\               *BIM*\                        Diagnosis                \[[@B23-ijms-17-00945],[@B24-ijms-17-00945],[@B25-ijms-17-00945],[@B26-ijms-17-00945],[@B27-ijms-17-00945]\]
                               GCCLs                                                     Cell cycle               *E2F1*\                                                
                                                                                                                  *CDKN1A*\                                              
                                                                                                                  *CDKN1B*\                                              
                                                                                                                  *CDKN1C*                                               

  **miR-107**                  GCTs\                                                     Invasion\                *CDK6*\                       LNM\                     \[[@B28-ijms-17-00945],[@B29-ijms-17-00945],[@B30-ijms-17-00945]\]
                               GCCLs                                                     Metastasis               *DICER1*                      Tumor stage\             
                                                                                                                                                Prognosis                

  **miR-1271**                 GCCLs                                                     ND                       *IGFIR*\                      ND                       \[[@B31-ijms-17-00945]\]
                                                                                                                  *MTOR*\                                                
                                                                                                                  *BCL2*                                                 

  **miR-129**                  GCTs\                                                     Cell proliferation\      *SOX2*\                       Prognosis\               \[[@B32-ijms-17-00945],[@B33-ijms-17-00945],[@B34-ijms-17-00945],[@B35-ijms-17-00945]\]
                               GCCLs                                                     Cell cycle               *SOX4*\                       Diagnosis                
                                                                                                                  *CDK6*\                                                
                                                                                                                  *PDCD2*                                                

  **miR-130a**                 GCCLs                                                     Metastasis\              ND                            ND                       \[[@B36-ijms-17-00945]\]
                                                                                         Invasion\                                                                       
                                                                                         Cell proliferation                                                              

  **miR-130b**                 GCCLs                                                     Apoptosis\               *RUNX3*\                      ND                       \[[@B37-ijms-17-00945]\]
                                                                                         Epigenetic regulation\   *BIM*                                                  
                                                                                         Cell proliferation                                                              

  **miR-135a**                 GCTs                                                      ND                       ND                            Prognosis                \[[@B38-ijms-17-00945]\]

  **miR-142-5p**               GCTs                                                      ND                       ND                            Poor Survival\           \[[@B39-ijms-17-00945]\]
                                                                                                                                                Prognosis                

  **miR-143**                  GCTs                                                      ND                       ND                            Tumor stage\             \[[@B40-ijms-17-00945]\]
                                                                                                                                                Scirrhous type\          
                                                                                                                                                Prognosis                

  **miR-145**                  GCTs\                                                     Angiogenesis             *CDH2*\                       Tumor stage\             \[[@B41-ijms-17-00945],[@B42-ijms-17-00945]\]
                               GCCLs                                                                              *ETS1*                        Scirrhous type\          
                                                                                                                                                Prognosis\               

  **miR-146a**                 GCCLs                                                     Apoptosis\               *IRAK1*\                      ND                       \[[@B43-ijms-17-00945],[@B44-ijms-17-00945],[@B45-ijms-17-00945]\]
                                                                                         Cell proliferation       *TRAF6*\                                               
                                                                                                                  *SMAD4*                                                

  **miR-148a**                 GCCLs                                                     Invasion\                *CDKN1B*                      ND                       \[[@B46-ijms-17-00945]\]
                                                                                         Metastasis\                                                                     
                                                                                         Cell proliferation\                                                             
                                                                                         Cell cycle                                                                      

  **miR-150**                  GCTs\                                                     Apoptosis\               *EGR2*                        Poor Survival\           \[[@B23-ijms-17-00945]\]
                               GCCLs                                                     Cell proliferation                                     Prognosis                

  **miR-15b**                  GCCLs                                                     Apoptosis                *BCL-2*                       ND                       \[[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B49-ijms-17-00945]\]

  **miR-155**                  GCCLs                                                     Apoptosis                *IKK-ε*\                      ND                       \[[@B50-ijms-17-00945],[@B51-ijms-17-00945],[@B52-ijms-17-00945],[@B53-ijms-17-00945]\]
                                                                                                                  *SMAD4*\                                               
                                                                                                                  *FADD*\                                                
                                                                                                                  *PLIα*                                                 

  **miR-16**                   GCCLs                                                     Chemosensitivity\        *BCL-2*                       ND                       \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B49-ijms-17-00945]\]
                                                                                         Apoptosis                                                                       

  **miR-17**                   GCCLs                                                     Cell cycle               *CDKN1A*\                     ND                       \[[@B54-ijms-17-00945]\]
                                                                                                                  *UBE2C*\                                               
                                                                                                                  *FBXO31*                                               

  **miR-181**                  GCCLs                                                     ND                       ND                            ND                       

  **miR-181b/c**               GCTs\                                                     Apoptosis\               *NOTCH4*\                     Differentiation\         \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B55-ijms-17-00945],[@B56-ijms-17-00945]\]
                               GCCLs                                                     Chemosensitivity         *K-RAS*\                      Invasive depth\          
                                                                                                                  *BCL-2*                       Tumor stage\             
                                                                                                                                                Prognosis                

  **miR-192**                  GCTs                                                      ND                       ND                            LNM\                     \[[@B57-ijms-17-00945]\]
                                                                                                                                                Prognosis                

  **miR-195**                  GCTs                                                      ND                       ND                            Recurrence               \[[@B58-ijms-17-00945]\]

  **miR-196a**                 GCTs\                                                     Metastasis\              *RADIXIN*                     Invasion depth\          \[[@B59-ijms-17-00945]\]
                               GCCLs                                                     Invasion\                                              Serosal invasion\        
                                                                                         Migration                                              Lymphatic invasion\      
                                                                                                                                                LNM\                     
                                                                                                                                                Distant metastasis\      
                                                                                                                                                TNM stage\               
                                                                                                                                                Peritoneal seeding\      
                                                                                                                                                Gross type\              
                                                                                                                                                Lauren subtype\          
                                                                                                                                                Prognosis                

  **miR-196a**                 GCTs\                                                     ND                       ND                            Differentiation          \[[@B60-ijms-17-00945]\]
                               GCCLs                                                                                                                                     

  **miR-196a-5p**              GCTs                                                      ND                       ND                            LNM\                     \[[@B61-ijms-17-00945]\]
                                                                                                                                                TNM stage\               
                                                                                                                                                Prognosis                

  **miR-196b**                 GCTs\                                                     Metastasis\              *RADIXIN*                     Invasion depth\          \[[@B59-ijms-17-00945]\]
                               GCCLs                                                     Invasion\                                              Serosal invasion\        
                                                                                         Migration                                              Lymphatic invasion\      
                                                                                                                                                LNM\                     
                                                                                                                                                Distant metastasis\      
                                                                                                                                                TNM stage\               
                                                                                                                                                Peritoneal seeding\      
                                                                                                                                                Gross type\              
                                                                                                                                                Prognosis                

  **miR-199a**                 GCTs\                                                     Cell proliferation\      *SMARCA2*\                    Recurrence\              \[[@B39-ijms-17-00945],[@B58-ijms-17-00945],[@B62-ijms-17-00945],[@B63-ijms-17-00945],[@B64-ijms-17-00945],[@B65-ijms-17-00945]\]
                               GCCLs                                                     Metastasis               *SMAD4*\                      Diagnosis\               
                                                                                                                  *MAP3K11*\                    Relapse                  
                                                                                                                  *ZHX1*                                                 

  **miR-1952**                 GCTs                                                      ND                       ND                            Relapse                  \[[@B58-ijms-17-00945]\]

  **miR-20a**                  GCTs\                                                     Cell cycle               *CDKN1A*                      Diagnosis                \[[@B23-ijms-17-00945],[@B24-ijms-17-00945],[@B25-ijms-17-00945]\]
                               GCCLs                                                                                                                                     

  **miR-20b**                  GCTs                                                      ND                       ND                            Poor Survival\           \[[@B23-ijms-17-00945],[@B66-ijms-17-00945]\]
                                                                                                                                                LNM\                     
                                                                                                                                                Distance metastasis\     
                                                                                                                                                TNM stage\               
                                                                                                                                                Prognosis                

  **miR-200c**                 GCTs\                                                     Metastasis\              *E-CDH*\                      ND                       \[[@B67-ijms-17-00945]\]
                               GCCLs                                                     Chemoresistance          *ZEB2*\                                                
                                                                                                                  *RHO E*                                                

  **miR-21**                   GCTs\                                                     Apoptosis\               *RECK*\                       LNM\                     \[[@B68-ijms-17-00945],[@B69-ijms-17-00945],[@B70-ijms-17-00945],[@B71-ijms-17-00945],[@B72-ijms-17-00945]\]
                               GCCLs                                                     Cell proliferation\      *PTEN*\                       Prognosis                
                                                                                         Invasion\                *SERPINI1*\                                            
                                                                                         Cell cycle\              *PDCD4*\                                               
                                                                                         Metastasis\              *NF-KB*\                                               
                                                                                         Differentiation          *CDKN1A*\                                              
                                                                                                                  *E2F5*\                                                
                                                                                                                  *CDKN1C*                                               

  **miR-210**                  Hp-positive human gastric biopsies/Hp-negative controls   ND                       *STMN1*\                      ND                       \[[@B73-ijms-17-00945]\]
                                                                                                                  *DIMT1*                                                

  **miR-211**                  Systematic integrative bioinformatics framework           ND                       ND                            Diagnosis                \[[@B16-ijms-17-00945]\]

  **miR-213**                  GCTs                                                      ND                       ND                            Diagnosis                \[[@B21-ijms-17-00945]\]

  **miR-214**                  GCTs                                                      ND                       ND                            Poor Survival\           \[[@B24-ijms-17-00945],[@B74-ijms-17-00945]\]
                                                                                                                                                Invasion depth\          
                                                                                                                                                Lymph node metastasis\   
                                                                                                                                                Prognosis                

  **miR-215**                  GCTs\                                                     Metastasis               *ALCAM*                       Prognosis                \[[@B71-ijms-17-00945]\]
                               GCCLs                                                                                                                                     

  **miR-221/222**              GCTs\                                                     Radioresistance\         *CDKN1A*\                     Prognosis                \[[@B27-ijms-17-00945],[@B68-ijms-17-00945]\]
                               GCCLs                                                     Cell cycle               *CDKN1B*\                                              
                                                                                                                  *CDKN1C*                                               

  **miR-2214**                 GCTs                                                      ND                       ND                            Advanced GC\             \[[@B75-ijms-17-00945]\]
                                                                                                                                                Prognosis                

  **miR-223**                  GCCLs                                                     Invasion\                *EPB41L3*\                    ND                       \[[@B76-ijms-17-00945]\]
                                                                                         Metastasis               *FBXW7*\                                               
                                                                                                                  *HCDC4*\                                               
                                                                                                                  *STMN1*                                                

  **miR-23a/b**                GCTs\                                                     Invasion\                *IL6R*\                       LNM\                     \[[@B77-ijms-17-00945],[@B78-ijms-17-00945],[@B79-ijms-17-00945]\]
                               GCCLs                                                     Cell proliferation       *IRF1*                        TNM stage\               
                                                                                                                                                Prognosis                

  **miR-25**                   GCTs\                                                     Invasion\                *CDKN1C*\                     LNM\                     \[[@B26-ijms-17-00945],[@B27-ijms-17-00945],[@B80-ijms-17-00945]\]
                               GCCLs                                                     Cell proliferation\      *BCL2L11*\                    Prognosis                
                                                                                         Migration                *FBXW7*\                                               
                                                                                                                  *LASTS2*\                                              
                                                                                                                  *RECK*                                                 

  **miR-27a**                  GCTs\                                                     Metastasis\              *APC*\                        Lymph node metastasis\   \[[@B23-ijms-17-00945],[@B81-ijms-17-00945]\]
                               GCCLs                                                     Cell proliferation       *PHB*                         Prognosis                

  **miR-335**                  GCTs                                                      Metastasis               ND                            Recurrence\              \[[@B82-ijms-17-00945],[@B83-ijms-17-00945]\]
                                                                                                                                                Prognosis                

  **miR-34**                   GCTs\                                                     Chemosensitivity\        *BCL-2*                       Tumor stage\             \[[@B17-ijms-17-00945],[@B47-ijms-17-00945],[@B48-ijms-17-00945],[@B55-ijms-17-00945],[@B56-ijms-17-00945]\]
                               GCCLs                                                     Apoptosis                                              Prognosis                

  **miR-342**                  GCCLs                                                     Chemosensitivity         ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-362**                  GCCLs                                                     Apoptosis                *NF-KB*                       ND                       \[[@B84-ijms-17-00945]\]

  **miR-363**                  GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-370**                  GCCLs                                                     Metastasis               *TGF-β-RII*                   ND                       \[[@B85-ijms-17-00945]\]

  **miR-375**                  GCTs\                                                     Apoptosis\               *PDK1*\                       Poor Survival\           \[[@B39-ijms-17-00945],[@B74-ijms-17-00945],[@B86-ijms-17-00945],[@B87-ijms-17-00945],[@B88-ijms-17-00945]\]
                               GCCLs                                                     Inhibits Helicobacter\   *YWHAZ*\                      Relapse/Recurrence\      
                                                                                         pylori-induced\          *JAK2*\                       Prognosis                
                                                                                         gastric carcinogenesis   *STAT3*                                                

  **miR-382**                  GCTs\                                                     Angiogenesis             *PTEN*                        ND                       \[[@B89-ijms-17-00945]\]
                               GCCLs                                                                                                                                     

  **miR-421**                  GCTs\                                                     ND                       *BAX*\                        Diagnosis                \[[@B90-ijms-17-00945],[@B91-ijms-17-00945]\]
                               GCCLs                                                                              *BCL-2*                                                

  **miR-43c**                  GCTs\                                                     Cell proliferation\      *VEZT*                        Epigenetic regulation\   \[[@B92-ijms-17-00945]\]
                               GCCLs                                                     Cell cycle                                             Prognosis                

  **miR-442a**                 GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B93-ijms-17-00945]\]

  **miR-451**                  GCTs\                                                     Apoptosis\               *MIF*                         Recurrence               \[[@B58-ijms-17-00945],[@B94-ijms-17-00945],[@B95-ijms-17-00945],[@B96-ijms-17-00945]\]
                               GCCLs                                                     Radiosensitivity                                                                

  **miR-4512**                 GCTs                                                      ND                       ND                            Relapse                  \[[@B39-ijms-17-00945]\]

  **miR-4732-5p**              GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B93-ijms-17-00945]\]

  **miR-4758-3p**              GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B93-ijms-17-00945]\]

  **miR-503**                  GCCLs                                                     ND                       *IGFIR*\                      ND                       \[[@B97-ijms-17-00945]\]
                                                                                                                  *BCL2*                                                 

  **miR-512-5p**               GCCLs                                                     Apoptosis                *MCL-1*                       ND                       \[[@B98-ijms-17-00945]\]

  **miR-514b**                 GCTs                                                      ND                       ND                            Diagnosis                \[[@B21-ijms-17-00945]\]

  **miR-517**                  GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-518f**                 GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-519e**                 GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-520a**                 GCCLs                                                     Chemoresistance          ND                            ND                       \[[@B17-ijms-17-00945]\]

  **miR-520d/h**               GCCLs                                                     Chemoresistance          *HDAC1*                       ND                       \[[@B17-ijms-17-00945]\]

  **miR-520d-3p**              GCTs\                                                     Cell proliferation\      *EPHA2*                       ND                       \[[@B99-ijms-17-00945]\]
                               GCCLs                                                     Migration\                                                                      
                                                                                         Invasion                                                                        

  **miR-548N**                 GCTs                                                      ND                       ND                            Diagnosis                \[[@B21-ijms-17-00945]\]

  **miR-630**                  GCTs\                                                     Invasion                 ND                            LNM\                     \[[@B100-ijms-17-00945]\]
                               GCCLs                                                                                                            Distant metastasis\      
                                                                                                                                                TNM stage\               
                                                                                                                                                Prognosis                

  **miR-650**                  GCTs                                                      ND                       ND                            Lymph node Metastasis\   \[[@B101-ijms-17-00945]\]
                                                                                                                                                Prognosis                

  **miR-708**                  GCTs                                                      ND                       ND                            Diagnosis                \[[@B16-ijms-17-00945]\]

  **miR-9**                    GCCLs                                                     Cell proliferation\      *CDX2*                        ND                       \[[@B102-ijms-17-00945]\]
                                                                                         Cell cycle                                                                      

  **miR-92**                   GCCLs                                                     Cell proliferation\      *FXR*                         ND                       \[[@B103-ijms-17-00945]\]
                                                                                         Invasion                                                                        

  **miR-92a**                  GCTs                                                      ND                       *E2F1*\                       Tumor growth\            \[[@B93-ijms-17-00945],[@B104-ijms-17-00945]\]
                                                                                                                  *HIPK1*                       Prognosis                

  **miR-93**                   GCCLs                                                     Apoptosis                *BIM*\                        ND                       \[[@B23-ijms-17-00945],[@B24-ijms-17-00945],[@B25-ijms-17-00945]\]
                                                                                                                  *DAB2*                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemoresistance drugs were cisplatin, 5-fluorouracil and hydroxy camptothecin. GCTs: Gastric cancer tissues, GCCLs: Gastric cancer cell lines, ND: not determined.
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###### 

Down-regulated miRNAs in tissues for GC.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tissue Tumor Suppressor miRs          Samples   Cell Functions                        Target (Official Gene Name)   Clinical Application            References
  ------------------------------------- --------- ------------------------------------- ----------------------------- ------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Let-7a**                            GCCLs     Cell proliferation\                   *RAB40C*\                     ND                              \[[@B105-ijms-17-00945],[@B106-ijms-17-00945],[@B107-ijms-17-00945]\]
                                                  Cell cycle\                           *HMGA2*\                                                      
                                                  Invasion                              *CDC34*\                                                      
                                                                                        *CCR7*                                                        

  **Let-7f**                            GCCLs     Metastasis                            *MYH9*                        ND                              \[[@B108-ijms-17-00945]\]

  **Let-7g**                            GCTs      ND                                    ND                            Diagnosis\                      \[[@B24-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945]\]
                                                                                                                      Invasion depth\                 
                                                                                                                      Lymph node metastasis\          
                                                                                                                      Poor Survival\                  
                                                                                                                      Chemoresistance\                
                                                                                                                      Prognosis                       

  **miR-1**                             GCTs      ND                                    ND                            Tumor stage\                    \[[@B111-ijms-17-00945]\]
                                                                                                                      Prognosis                       

  **miR-9**                             GCTs\     Cell proliferation\                   *ETS1*\                       ND                              \[[@B102-ijms-17-00945],[@B112-ijms-17-00945],[@B113-ijms-17-00945],[@B114-ijms-17-00945]\]
                                        GCCLs     Metastasis                            *NFKB1*\                                                      
                                                                                        *CCND1*\                                                      
                                                                                        *CUL4A*\                                                      
                                                                                        *CDX2*                                                        

  **miR-10b**                           GCTs\     Cell proliferation                    *MAPRE1*\                     ND                              \[[@B19-ijms-17-00945],[@B115-ijms-17-00945],[@B116-ijms-17-00945]\]
                                        GCCLs                                           *CCND1*                                                       

  **miR-101**                           GCTs\     Metastasis                            *EZH2*\                       ND                              \[[@B117-ijms-17-00945],[@B118-ijms-17-00945],[@B119-ijms-17-00945],[@B120-ijms-17-00945]\]
                                        GCCLs                                           *COX2*\                                                       
                                                                                        *MCL1*\                                                       
                                                                                        *FOS*                                                         

  **miR-1207-5p**                       GCTs\     ND                                    ND                            LNM\                            \[[@B121-ijms-17-00945]\]
                                        GCCLs                                                                         Lymphovascular invasion\        
                                                                                                                      Stromal reaction type\          
                                                                                                                      TNM stage\                      
                                                                                                                      Prognosis                       

  **miR-124**                           GCCLs     Cell proliferation\                   *ROCK1*                       ND                              \[[@B122-ijms-17-00945]\]
                                                  Invasion                                                                                            

  **miR-124a**                          GCCLs     Cell cycle                            *CDK6*                        ND                              \[[@B123-ijms-17-00945]\]

  **miR-1246, miR-302a and miR-4448**   GCCLs     ND                                    *DYRK1A*                      ND                              \[[@B124-ijms-17-00945]\]

  **miR-125a-3p**                       GCTs\     ND                                    ND                            Invasion\                       \[[@B125-ijms-17-00945]\]
                                        GCCLs                                                                         LNM\                            
                                                                                                                      Liver metastasis\               
                                                                                                                      Tumor stage\                    
                                                                                                                      Tumor size\                     
                                                                                                                      Peritoneal dissemination\       
                                                                                                                      Prognosis                       

  **miR-125a-5p**                       GCTs\     Cell proliferation\                   *ERBB2*\                      Invasion depth\                 \[[@B24-ijms-17-00945],[@B126-ijms-17-00945],[@B127-ijms-17-00945]\]
                                        GCCLs     Metastasis\                           *E2F3*                        Liver metastasis\               
                                                  Invasion\                                                           Tumor stage\                    
                                                  Migration                                                           Tumor size\                     
                                                                                                                      Poor Survival\                  
                                                                                                                      Prognosis                       

  **miR-125-5p**                        GCTs      ND                                    ND                            Poor Survival\                  \[[@B126-ijms-17-00945]\]
                                                                                                                      Prognosis                       

  **miR-126**                           GCTs\     Cell cycle\                           *CRK*\                        Lymph node metastasis\          \[[@B128-ijms-17-00945],[@B129-ijms-17-00945],[@B130-ijms-17-00945]\]
                                        GCCLs     Cell proliferation\                   *PI3KR2*\                     Prognosis                       
                                                  Metastasis\                           *PLK2*                                                        
                                                  Invasion\                                                                                           
                                                  Migration                                                                                           

  **miR-126**                           GCTs      ND                                    ND                            Advanced GC                     \[[@B128-ijms-17-00945]\]

  **miR-126**                           GCCLs     Chemoresistance                       ND                            ND                              \[[@B109-ijms-17-00945]\]

  **miR-129**                           GCCLs     Proliferation\                        *CDK6*                        ND                              \[[@B131-ijms-17-00945]\]
                                                  Cell cycle                                                                                          

  **miR-129-1-3p**                      GCCLs     Migration                             ND                            ND                              \[[@B34-ijms-17-00945]\]

  **miR-129-2**                         GCTs\     Cell proliferation                    *SOX4*                        Epigenetic regulation\          \[[@B35-ijms-17-00945]\]
                                        GCCLs                                                                         Differentiation                 

  **miR-141**                           GCCLs     Invasion\                             ND                            ND                              \[[@B132-ijms-17-00945]\]
                                                  Cell proliferation\                                                                                 
                                                  Metastasis                                                                                          

  **miR-142-5p**                        GCTs      ND                                    ND                            Relapse                         \[[@B39-ijms-17-00945]\]

  **miR-143**                           GCCLs     Cell proliferation                    *AKT*                         ND                              \[[@B133-ijms-17-00945]\]

  **miR-145**                           GCCLs     Cell proliferation                    *IRS1*                        ND                              \[[@B133-ijms-17-00945]\]

  **miR-146a**                          GCTs\     Invasion\                             *EGFR*\                       Lymph node metastasis\          \[[@B24-ijms-17-00945],[@B134-ijms-17-00945]\]
                                        GCCLs     Migration                             *IRAK1*                       Venous invasion\                
                                                                                                                      Poor Survival\                  
                                                                                                                      Prognosis                       

  **miR-148a**                          GCTs\     ND                                    ND                            Advanced GC                     \[[@B135-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-148a**                          GCTs\     Metastasis                            *DNMT1*\                      Distant metastasis\             \[[@B46-ijms-17-00945],[@B135-ijms-17-00945],[@B136-ijms-17-00945],[@B137-ijms-17-00945]\]
                                        GCCLs                                           *CDKN1B*\                     Organ invasion\                 
                                                                                        *ROCK1*                       Peritoneal invasion\            
                                                                                                                      Prognosis                       

  **miR-148b**                          GCTs\     Cell proliferation                    *CCKBR*                       ND                              \[[@B138-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-148**                           GCTs\     ND                                    ND                            Lymph node metastasis\          \[[@B135-ijms-17-00945]\]
                                        GCCLs                                                                         Prognosis                       

  **miR-15b**                           GCTs\     Chemoresistance                       ND                            ND                              \[[@B47-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-153**                           GCTs\     Migration\                            ND                            LNM\                            \[[@B139-ijms-17-00945]\]
                                        GCCLs     Invasion                                                            Prognosis                       

  **miR-155**                           GCTs\     Cell proliferation\                   *C-MYC*                       ND                              \[[@B130-ijms-17-00945]\]
                                        GCCLs     Invasion\                                                                                           
                                                  Migration                                                                                           

  **miR-16**                            GCTs\     Chemoresistance                       *ND*                          ND                              \[[@B47-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-181c**                          GCTs\     Cell proliferation                    *NOTCH4*\                     Transcriptional activation      \[[@B56-ijms-17-00945]\]
                                        GCCLs                                           *KRAS*                                                        

  **miR-185**                           GCTs\     ND                                    ND                            Prognosis\                      \[[@B140-ijms-17-00945]\]
                                        GCCLs                                                                         TNM stage                       

  **miR-19b**                           GCTs\     ND                                    ND                            Diagnosis                       \[[@B104-ijms-17-00945],[@B141-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-192**                           GCTs\     ND                                    ND                            Tumor sizes\                    \[[@B142-ijms-17-00945]\]
                                        GCCLs                                                                         Borrmann type\                  
                                                                                                                      Prognosis                       

  **miR-193b**                          GCTs\     Invasion\                             ND                            Differentiation\                \[[@B60-ijms-17-00945]\]
                                        GCCLs     Metastasis                                                          Lauren type\                    
                                                                                                                      Tumor stage\                    
                                                                                                                      Prognosis                       

  **miR-196a**                          GCTs\     Chemoresistance                       ND                            ND                              \[[@B109-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-20a**                           GCTs\     ND                                    ND                            Tumor stage\                    \[[@B111-ijms-17-00945]\]
                                        GCCLs                                                                         Prognosis                       

  **miR-200b**                          GCTs\     Invasion\                             ND                            ND                              \[[@B143-ijms-17-00945]\]
                                        GCCLs     metastasis                                                                                          

  **miR-200 family**                    GCTs\     EMT\                                  *ZEB1*\                       ND                              \[[@B109-ijms-17-00945],[@B144-ijms-17-00945],[@B145-ijms-17-00945],[@B146-ijms-17-00945]\]
                                        GCCLs     Chemoresistance\                      *ZEB2*\                                                       
                                                  Cell proliferation\                   *CDH1*\                                                       
                                                  Invasion\                             *BCL2*\                                                       
                                                  Migration\                            *XIAP*                                                        
                                                  Apoptosis                                                                                           

  **miR-203**                           GCTs\     Cell proliferation\                   *ABL1*                        ND                              \[[@B147-ijms-17-00945],[@B148-ijms-17-00945]\]
                                        GCCLs     Invasion                                                                                            

  **miR-204**                           GCTs\     Cell proliferation\                   *EZR*\                        ND                              \[[@B149-ijms-17-00945]\]
                                        GCCLs     Invasion                              *SOX4*                                                        

  **miR-206**                           GCTs\     ND                                    *CCND2*                       Venous invasion\                \[[@B150-ijms-17-00945],[@B151-ijms-17-00945]\]
                                        GCCLs                                                                         LNM\                            
                                                                                                                      Hematogenous recurrence\        
                                                                                                                      PStage\                         
                                                                                                                      Prognosis                       

  **miR-212**                           GCTs\     Cell proliferation                    *MECP2*                       ND                              \[[@B152-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-215**                           GCTs\     ND                                    ND                            Borrmann type\                  \[[@B142-ijms-17-00945]\]
                                        GCCLs                                                                         Tumor sizes\                    
                                                                                                                      pT stage\                       
                                                                                                                      Prognosis                       

  **miR-217**                           GCTs\     Differentiation Distant Metastasis\   ND                            Tumor size\                     \[[@B153-ijms-17-00945]\]
                                        GCCLs     Invasion                                                            TNM stage\                      
                                                                                                                      Prognosis                       

  **miR-218**                           GCTs\     Metastasis\                           *ROBO1*\                      Lymph node metastasis\          \[[@B154-ijms-17-00945],[@B155-ijms-17-00945],[@B156-ijms-17-00945],[@B157-ijms-17-00945],[@B158-ijms-17-00945],[@B159-ijms-17-00945],[@B160-ijms-17-00945]\]
                                        GCCLs     Invasion                              *COX2*\                       Transcriptional activation\     
                                                                                        *NFkB*\                       Prognosis\                      
                                                                                        *ECOP*\                       Advanced gastric cancer\        
                                                                                        *VOPP1*                       Prognosis                       

  **miR-22**                            GCTs\     ND                                    *SP1*                         LNM\                            \[[@B151-ijms-17-00945],[@B161-ijms-17-00945]\]
                                        GCCLs                                                                         Distant metastasis\             
                                                                                                                      Tumor stage\                    
                                                                                                                      Prognosis                       

  **miR-223**                           GCTs\     Metastasis                            *STMN1*                       ND                              \[[@B162-ijms-17-00945],[@B163-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-24**                            GCCLs     Cell cycle                            *AE1*                         ND                              \[[@B164-ijms-17-00945],[@B165-ijms-17-00945]\]

  **miR-27a**                           GCTs\     ND                                    ND                            Tumor stage\                    \[[@B111-ijms-17-00945]\]
                                        GCCLs                                                                         Lymph node metastasis\          
                                                                                                                      TNM stag\                       
                                                                                                                      Prognosis                       

  **miR-29a**                           GCTs\     Cell proliferation\                   *P42.3*\                      ND                              \[[@B166-ijms-17-00945],[@B167-ijms-17-00945],[@B168-ijms-17-00945]\]
                                        GCCLs     Cell cycle\                           *CDC42*                                                       
                                                  Metastasis                                                                                          

  **miR-29c**                           GCTs\     ND                                    ND                            Venous invasion\                \[[@B169-ijms-17-00945]\]
                                        GCCLs                                                                         TNM stage\                      
                                                                                                                      Prognosis                       

  **miR-30b**                           GCTs\     Apoptosis                             *PAI-1*                       ND                              \[[@B170-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-31**                            GCTs\     Chemoresistance                       ND                            ND                              \[[@B109-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-335**                           GCTs\     Metastasis\                           *BCL-W*\                      Lymph node metastasis\          \[[@B171-ijms-17-00945]\]
                                        GCCLs     Cell invasion                         *SP1*                         Prognosis\                      
                                                                                                                      Invasion of lymphatic vessels   

  **miR-338**                           GCTs\     Chemoresistance                       ND                            ND                              \[[@B109-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-34a**                           GCTs\     ND                                    *BCL2*\                       Lymph node involvement\         \[[@B172-ijms-17-00945],[@B173-ijms-17-00945]\]
                                        GCCLs                                           *PDGFR*\                      TNM stage\                      
                                                                                        *YY1*                         Differentiation\                
                                                                                                                      Recurrence\                     
                                                                                                                      Prognosis                       

  **miR-34**                            GCTs\     Cell proliferation                    *BCL2*\                       TNM stage\                      \[[@B111-ijms-17-00945],[@B172-ijms-17-00945]\]
                                        GCCLs                                           *NOTCH1*\                     Transcription\                  
                                                                                        *HMGA2*\                      Epigenetic regulation\          
                                                                                        *C-MYC*\                      Prognosis                       
                                                                                        *SIRT1*                                                       

  **miR-370**                           GCTs\     ND                                    ND                            Diagnosis                       \[[@B31-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-375**                           GCTs\     Apoptosis\                            *PDK1*\                       ND                              \[[@B86-ijms-17-00945],[@B174-ijms-17-00945],[@B175-ijms-17-00945]\]
                                        GCCLs     Cell proliferation                    *YWHAZ*\                                                      
                                                                                        *JAK2*\                                                       
                                                                                        *ERBB2*\                                                      
                                                                                        *STAT3*\                                                      
                                                                                        *TP53*                                                        

  **miR-410**                           GCTs\     migration\                            *MDM2*                        ND                              \[[@B176-ijms-17-00945]\]
                                        GCCLs     invasion                                                                                            

  **miR-423-5p**                        GCTs\     ND                                    ND                            TNM stage\                      \[[@B111-ijms-17-00945]\]
                                        GCCLs                                                                         Prognosis                       

  **miR-429**                           GCTs\     Cell proliferation\                   *C-MYC*\                      Lymph node metastasis\          \[[@B177-ijms-17-00945]\]
                                        GCCLs     Apoptosis                             *BCL2*\                       Prognosis                       
                                                                                        *XIAP*                                                        

  **miR-433**                           GCTs\     ND                                    *GRB2*                        Diagnosis\                      \[[@B24-ijms-17-00945],[@B86-ijms-17-00945],[@B109-ijms-17-00945],[@B110-ijms-17-00945],[@B174-ijms-17-00945]\]
                                        GCCLs                                                                         Invasion depth\                 
                                                                                                                      Lymph node metastasis\          
                                                                                                                      Poor Survival\                  
                                                                                                                      Prognosis                       

  **miR-449**                           GCTs\     Cell proliferation\                   *GEMININ*\                    ND                              \[[@B131-ijms-17-00945],[@B166-ijms-17-00945],[@B178-ijms-17-00945]\]
                                        GCCLs     Apoptosis\                            *P42.3*\                                                      
                                                  Cell cycle                            *CCNE2*\                                                      
                                                                                        *GMNN*\                                                       
                                                                                        *MET*\                                                        
                                                                                        *CCNE3*\                                                      
                                                                                        *SIRT1*\                                                      
                                                                                        *CDK6*                                                        

  **miR-451**                           GCTs\     Cell proliferation                    *MIF*                         Poor Survival\                  \[[@B24-ijms-17-00945],[@B94-ijms-17-00945]\]
                                        GCCLs                                                                         Prognosis                       

  **miR-486**                           GCTs\     Cell proliferation                    *OLFM4*                       ND                              \[[@B179-ijms-17-00945],[@B180-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-512-5p**                        GCTs\     Cell proliferation                    *MCI-1*                       ND                              \[[@B98-ijms-17-00945]\]
                                        GCCLs                                                                                                         

  **miR-520d-3p**                       GCTs\     ND                                    ND                            Invasion depth\                 \[[@B99-ijms-17-00945]\]
                                        GCCLs                                                                         LNM\                            
                                                                                                                      Tumor stage\                    
                                                                                                                      Prognosis                       

  **miR-610**                           GCTs\     Invasion\                             ND                            ND                              \[[@B181-ijms-17-00945]\]
                                        GCCLs     Metastasis                                                                                          

  **miR-7**                             GCTs\     Invasion Metastasis\                  ND                            ND                              \[[@B109-ijms-17-00945],[@B182-ijms-17-00945]\]
                                        GCCLs     Chemoresistance                                                                                     

  **miR-9**                             GCTs\     Cell proliferation\                   *RAB34*\                      Diagnosis                       \[[@B24-ijms-17-00945],[@B172-ijms-17-00945],[@B183-ijms-17-00945]\]
                                        GCCLs     Cell cycle                            *CDX2*\                                                       
                                                                                        *NFKB1*                                                       

  **miR-98**                            GCTs\     Chemoresistance                       ND                            ND                              \[[@B109-ijms-17-00945]\]
                                        GCCLs                                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Chemoresistance drugs were cisplatin, 5-fluorouracil and hydroxy camptothecin. GCTs: Gastric cancer tissues, GCCLs: Gastric cancer cell lines, ND: not determined.
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###### 

Up-regulated circulating miRNAs for GC.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Circulating OncomiRs   Samples         Methods                Sensitivity   Specificity   AUC     Target (Official Gene Name)   Clinical Application         References
  ---------------------- --------------- ---------------------- ------------- ------------- ------- ----------------------------- ---------------------------- --------------------------------------------------------------------------------------------
  **miR-1**              164 GC\         Microarray + qRT-PCR   79.3          86.5          0.879   ND                            Diagnosis                    \[[@B111-ijms-17-00945]\]
                         127 HC                                                                                                                                

  **miR-106a**           90 GC\          Microarray + qRT-PCR   48.2          90.2          0.684   ND                            Diagnosis                    \[[@B184-ijms-17-00945]\]
                         27 HC                                                                                                                                 

  **miR-106a**           69 GC\          Microarray + qRT-PCR   85.5          80            0.879   ND                            Diagnosis                    \[[@B185-ijms-17-00945]\]
                         30 HC                                                                                                                                 

  **miR-106b**           69 GC\          Microarray + qRT-PCR   ND            ND            0.72    ND                            Diagnosis                    \[[@B185-ijms-17-00945]\]
                         30 HC                                                                                                                                 

  **miR-106b**           40 Pre GC\      qRT-PCR                ND            ND            ND      ND                            TNM stage\                   \[[@B186-ijms-17-00945]\]
                         20 Post GC                                                                                               Diagnosis\                   
                                                                                                                                  Prognosis                    

  **miR-17**             90 GC\          Microarray + qRT-PCR   48.2          90.2          0.743   ND                            Diagnosis                    \[[@B184-ijms-17-00945]\]
                         27 HC                                                                                                                                 

  **miR-17-5p**          79 Pre GC\      qRT-PCR                ND            ND            ND      ND                            Diagnosis\                   \[[@B54-ijms-17-00945]\]
                         30 Post GC\                                                                                              Poor Survival\               
                         6 Relapse GC                                                                                             Differentiation\             
                                                                                                                                  TNM stages\                  
                                                                                                                                  Prognosis                    

  **miR-18a**            82 GC\          qRT-PCR                ND            ND            ND      ND                            Poor Survival\               \[[@B54-ijms-17-00945],[@B187-ijms-17-00945]\]
                         65 HC                                                                                                    LNM\                         
                                                                                                                                  Pathological grade\          
                                                                                                                                  Prognosis                    

  **miR-18a**            104 GC\         qRT-PCR                ND            ND            ND      ND                            Diagnosis                    \[[@B188-ijms-17-00945]\]
                         65 HC                                                                                                                                 

  **miR-192**            12 GC\          qRT-PCR                ND            ND            0.732   ND                            Diagnosis\                   \[[@B189-ijms-17-00945]\]
                         12 HC                                                                                                    Distant metastasis\          
                                                                                                                                  No Distant metastasis        

  **miR-199a-3p**        30 EGC\         Microarray + qRT-PCR   0.76          0.74          0.818   ND                            Diagnosis                    \[[@B190-ijms-17-00945],[@B191-ijms-17-00945]\]
                         70 HC                                                                                                                                 

  **miR-20a**            79 Pre GC\      qRT-PCR                ND            ND            ND      ND                            Poor Survival\               \[[@B54-ijms-17-00945]\]
                         30 Post GC\                                                                                              Differentiation\             
                         6 Relapse GC                                                                                             TNM stages\                  
                                                                                                                                  Prognosis                    

  **miR-20a**            164 GC\         Microarray + qRT-PCR   79.3          86.5          0.879   ND                            Diagnosis                    \[[@B111-ijms-17-00945]\]
                         127 HC                                                                                                                                

  **miR-200c**           67 GC\          qRT-PCR                65.4          100           0.715   *BCL2*\                       Diagnosis\                   \[[@B192-ijms-17-00945],[@B193-ijms-17-00945]\]
                         15 HC                                                                      *XIAP*                        LNM\                         
                                                                                                                                  Poor Survival\               
                                                                                                                                  Prognosis                    

  **miR-21**             174 GC\         Microarray + qRT-PCR   56.7          94.9          0.81    ND                            Diagnosis                    \[[@B194-ijms-17-00945]\]
                         39 HC                                                                                                                                 

  **miR-21**             69 GC\          qRT-PCR                ND            ND            ND      *RECK*\                       Venous invasion\             \[[@B68-ijms-17-00945],[@B71-ijms-17-00945],[@B195-ijms-17-00945],[@B196-ijms-17-00945]\]
                         42 Pre GC\                                                                 *PTEN*\                       Poor Survival\               
                         42 Post GC                                                                 *SERPINI1*                    Prognosis Differentiation\   
                                                                                                                                  LNM\                         
                                                                                                                                  Poor Survival\               
                                                                                                                                  Prognosis                    

  **miR-21**             103 GC\         qRT-PCR                ND            ND            ND      ND                            Diagnosis\                   \[[@B197-ijms-17-00945]\]
                         103 HC                                                                                                   Prognosis                    

  **miR-218**            68 GC\          qRT-PCR                ND            ND            ND      *ECOP*                        Metastasis\                  \[[@B155-ijms-17-00945],[@B198-ijms-17-00945]\]
                         56 HC                                                                                                    Tumor stage\                 
                                                                                                                                  Poor Survival\               
                                                                                                                                  Prognosis                    

  **miR-221**            82 GC\          qRT-PCR                ND            ND            ND      *CDKN1B*\                     Differentiation\             \[[@B27-ijms-17-00945],[@B199-ijms-17-00945],[@B200-ijms-17-00945]\]
                         46 Dysplasia\                                                              *CDKN1C*\                     Poor Survival\               
                         128 SG or CAG                                                              *PTEN*                        Prognosis                    

  **miR-221**            82 GC\          qRT-PCR                82.4          58.8          ND      ND                            Diagnosis                    \[[@B199-ijms-17-00945]\]
                         82 HC                                                                                                                                 

  **miR-222**            114 GC\         qRT-PCR                66.1          88.3          0.85    *CDKN1B*\                     Diagnosis\                   \[[@B27-ijms-17-00945],[@B200-ijms-17-00945],[@B201-ijms-17-00945],[@B202-ijms-17-00945]\]
                         36 CAG\                                                                    *CDKN1C*\                     LNM\                         
                         56 HC                                                                      *PTEN*\                       TNM stages\                  
                                                                                                    *RECK*                        Serosal Invasion\            
                                                                                                                                  Poor Survival\               
                                                                                                                                  Prognosis                    

  **miR-25**             70 GC\          qRT-PCR                ND            ND            ND      *CDKN1C*\                     LNM\                         \[[@B26-ijms-17-00945],[@B27-ijms-17-00945],[@B80-ijms-17-00945],[@B203-ijms-17-00945]\]
                         70 HC                                                                      *BCL2L11*\                    TNM stage\                   
                                                                                                    *FBXW7*                       Poor Survival\               
                                                                                                                                  Prognosis                    

  **miR-25**             40 Pre GC\      qRT-PCR                ND            ND            ND      ND                            TNM stage\                   \[[@B186-ijms-17-00945]\]
                         20 Post GC                                                                                               Diagnosis\                   
                                                                                                                                  Prognosis                    

  **miR-27a**            82 GC           qRT-PCR                ND            ND            ND      *PHB*\                        Metastasis\                  \[[@B81-ijms-17-00945],[@B204-ijms-17-00945],[@B205-ijms-17-00945]\]
                                                                                                    *APC*                         Poor Survival\               
                                                                                                                                  Recurrent\                   
                                                                                                                                  Prognosis                    

  **miR-27a**            164 GC\         Microarray + qRT-PCR   79.3          86.5          0.879   ND                            Diagnosis                    \[[@B111-ijms-17-00945]\]
                         127 HC                                                                                                                                

  **miR-34**             164 GC\         Microarray + qRT-PCR   79.3          86.5          0.879   ND                            Diagnosis                    \[[@B111-ijms-17-00945]\]
                         127 HC                                                                                                                                

  **miR-376c**           82 GC\          qRT-PCR                82.4          58.8          ND      ND                            Diagnosis Differentiation\   \[[@B199-ijms-17-00945]\]
                         82 HC\                                                                                                   Poor Survival\               
                         46 dysplasia\                                                                                            Prognosis                    
                         128 SG\                                                                                                                               
                         or CAG                                                                                                                                

  **miR-378**            61 GC\          qRT-PCR                87.5          70.7          0.861   ND                            Diagnosis                    \[[@B206-ijms-17-00945]\]
                         61 HC                                                                                                                                 

  **miR-421**            90 GC\          qRT-PCR                ND            ND            ND      ND                            Diagnosis                    \[[@B207-ijms-17-00945]\]
                         90 HC                                                                                                                                 

  **miR-423-5P**         164 GC\         Microarray + qRT-PCR   79.3          86.5          0.879   ND                            Diagnosis                    \[[@B111-ijms-17-00945]\]
                         127 HC                                                                                                                                

  **miR-451**            56 GC\          Microarray + qRT-PCR   96            100           0.96    ND                            Diagnosis                    \[[@B208-ijms-17-00945]\]
                         30 HC                                                                                                                                 

  **miR-486**            56 GC\          Microarray + qRT-PCR   86            97            0.92    ND                            Diagnosis                    \[[@B208-ijms-17-00945]\]
                         30 HC                                                                                                                                 

  **miR-744**            82 GC\          qRT-PCR                82.4          58.8          ND      ND                            Diagnosis Differentiation\   \[[@B199-ijms-17-00945]\]
                         82 HC\                                                                                                   Poor Survival\               
                         46 dysplasia\                                                                                            Prognosis                    
                         128 SG\                                                                                                                               
                         or CAG                                                                                                                                

  **miR-93**             40 Pre GC\      qRT-PCR                ND            ND            ND      ND                            TNM stage\                   \[[@B186-ijms-17-00945]\]
                         20 Post GC                                                                                               Diagnosis\                   
                                                                                                                                  Prognosis                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AG: chronic atrophic gastritis; GC: Gastric cancer; HC: Healthy control; LNM: Lymph node metastasis; Pre: pre-operative; Post: post-operative; SG: superficial gastritis; qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction; AUC: Area under curve; ND: not determined.

ijms-17-00945-t004_Table 4

###### 

Down-regulated circulating miRNAs for GC.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Circulating Tumor Suppressor miRs   Samples   Methods                Sensitivity   Specificity   AUC     Target (Official Gene Name)   Clinical Application     References
  ----------------------------------- --------- ---------------------- ------------- ------------- ------- ----------------------------- ------------------------ -------------------------------------------------
  **miR-122**                         12 GC\    qRT-PCR                ND            ND            0.808   ND                            Distance metastases\     \[[@B189-ijms-17-00945]\]
                                      12 HC                                                                                              Poor Survival\           
                                                                                                                                         Prognosis\               
                                                                                                                                         No Distant metastasis\   
                                                                                                                                         Diagnosis                

  **miR-195-5p**                      20 GC\    qRT-PCR                ND            ND            ND      ND                            Prognosis                \[[@B209-ijms-17-00945],[@B210-ijms-17-00945]\]
                                      190 HC                                                                                                                      

  **miR-203**                         154 GC\   qRT-PCR                ND            ND            ND      ND                            Gender\                  \[[@B211-ijms-17-00945]\]
                                      22 HC                                                                                              Lymphatic invasion\      
                                                                                                                                         Venous invasion\         
                                                                                                                                         Peritoneal metastasis\   
                                                                                                                                         Distance metastasis\     
                                                                                                                                         LNM\                     
                                                                                                                                         Liver metastasis\        
                                                                                                                                         TNM stage\               
                                                                                                                                         Poor Survival\           
                                                                                                                                         Prognosis                

  **miR-218**                         68 GC\    qRT-PCR                ND            ND            ND      *ECOP*                        Metastasis\              \[[@B155-ijms-17-00945],[@B198-ijms-17-00945]\]
                                      56 HC                                                                                              Tumor stage\             
                                                                                                                                         Poor Survival\           
                                                                                                                                         Prognosis                

  **miR-375**                         NA        Microarray + qRT-PCR   0.85          0.80          0.835   ND                            Prognosis                \[[@B210-ijms-17-00945]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GC: Gastric cancer; HC: Healthy control; Pre: pre-operative; Post: post-operative; qRT-PCR: Quantitative reverse transcriptase polymerase chain reaction; AUC: Area under curve; ND: not determined.

[^1]: These authors contributed equally to this work.
